ClinicalTrials.gg
Status unknownNCT02917291SPINEUpdated Sep 16, 2021

Safety and Preliminary Efficacy of FAB117-HC in Patients With Acute Traumatic Spinal Cord Injury

A Phase 1/2 interventional study of FAB117-HC and Control group in Acute Traumatic Spinal Cord Injury, sponsored by Ferrer Internacional S.A.. Status unknown at 9 sites in Spain. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-09-16.

Sponsored by Ferrer Internacional S.A. · Phase 1/2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Sep 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
16 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Spinal Cord Injuries with a site in Spain — 11 open to participants now, 13 under way, 1 of them phase 3. Spinal Cord Injuries · Spain.

Planned enrollment
18th of 55
48 · median 30
Started
2016
with 3 others
Phase 1/2
7 of 59
2 open now
Registered
17th of 59
by date

Among the 59 studies in Spinal Cord Injuries with a site in Spain, this one is the 18th largest by planned enrollment of the 55 interventional ones that give a count, is one of 4 that started in 2016, is one of 7 in phase 1/2, and was the 17th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

11 of the 59 studies in Spinal Cord Injuries with a site in Spain are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 16 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Spinal Cord Injuries with a site in Spain, or all of them as a file.
02

Study summary

The main objective of the study is the evaluation of the safety and tolerability of FAB117-HC (a medicinal product containing human allogeneic adipose derived adult mesenchymal stem cells expanded and pulsed with H2O2, HC016 cells) administered at a single-time point to patients with acute thoracic traumatic spinal cord injury (SCI). The study will also include initial exploration of potential clinical efficacy. Dose levels of 20 million and 40 million cells will be administered.

Read the detailed description

FAB117-HC is an investigational medicinal product whose active substance is HC016, allogeneic adipose-derived adult mesenchymal stem cells expanded and pulsed with H2O2.

The main purpose of this study is to evaluate the safety and tolerability of a single administration of FAB117-HC using: a) two sequential escalating doses administered between 72 and 120 hours post-injury, to patients with acute traumatic SCI with ASIA Impairment Scale (AIS) grade A; and b) the determined maximum tolerated dose administered up to 96 h post-injury to patients with AIS grading of A or B. The study includes also initial exploration of efficacy.

Treatment is administered by intramedullary injection into the injured spinal cord, during the decompression and stabilization surgery (DSS) of the fracture. DSS is routinely performed on almost all SCI patients.

The study has been divided into two phases:

Phase 1 (open label): 8 AIS A patients with lesion located between D1 and D12 will be included in 2 sequential cohorts.

Phase 2 (randomized, controlled, double-blind): Up to 40 AIS A or B patients with lesion located between D1 and D12, will be randomly divided into two groups (control and treated) that will be balanced in AIS grade.

03

Conditions studied

  • Acute Traumatic Spinal Cord Injury

Keywords

  • Trauma Spinal Cord
  • Thoracic Acute Spinal Cord Injury
  • Neurosurgery
  • Cell Therapy
  • ATMP
  • HC016 adipose mesenchymal stem cell
  • SPINE
04

Who can participate

Ages eligible
16 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Phase 1 (2 Cohorts)

  1. Male or female subjects ≥ 16 to ≤ 70 years.
  2. ASIA impairment grade A.
  3. Either a level of injury between D1-D12 both inclusive (cohorts 1 and 2).
  4. Single traumatic spinal cord injury as defined by MRI.
  5. Injury occurred between 72 and 120h before undergoing DSS and treatment.
  6. Clinically and haemodynamically stable, under medical criteria, enough to undergo DSS.
  7. Able to give either in writing or orally in the presence of a witness.

Phase 2 (2 Groups)

  1. Male or female subjects ≥ 16 to ≤ 70 years.
  2. ASIA impairment grade A or B.
  3. An injury between D1 and D12, both inclusive.
  4. Single traumatic spinal cord injury as defined by MRI.
  5. Injury occurring up to 96 h before undergoing DSS and treatment.
  6. Clinically and haemodynamically stable enough, under medical criteria, to undergo DSS.
  7. Able to give informed consent either in writing or orally in the presence of a witness.

Exclusion criteria

Exclusion Criteria:

  1. Participated in a previous clinical study and received an product within 28 days of SCI (within 5 years of SCI if the investigational product is a cell-based medicine).
  2. Radiological or MRI or DSS evidence of complete or partial spinal cord transection.
  3. Inability to unequivocally identify the injection sites.
  4. Multiple injuries to the neurological spinal cord at different levels.
  5. Patients with any of these additional conditions:

    1. Penetrating spinal cord injuries.
    2. Associated trauma or injury to the brachial and / or lumbosacral plexus.
  6. Active infection in the surgical area.
  7. Haemodynamic instability contraindicating DSS procedure in the time frame defined for inclusion in the trial.
  8. Multiple organ failure.
  9. Severe multiple trauma that hampers the stabilization procedure in the defined term for the inclusion in the trial.
  10. Significant head injury (Score on the Glasgow scale less than or equal to 13 and / or abnormal MRI/CT, meaning oedema, axonal lesion and/or haemorrhage) or other injury that in the investigator's opinion is sufficient to interfere with the assessment of spinal cord function or compromise the validity of patient data.
  11. Patients undergoing mechanical ventilation that does not allow a prior clinical examination.
  12. Inability to communicate with the neurological examiner so that the validity of patient data could be unreliable.
  13. Coma or significant impairment in the level of consciousness, including unconsciousness due to sedative-analgesic medications, that interferes with the performance or interpretation of assessments specific in the protocol.
  14. Preexisting or current significant diseases such as , , epilepsy, neoplastic disease or other diseases that could cause neurological deficits including syphilis, myelopathy, and polyneuropathy.
  15. Background or acute episode of Guillain-Barre syndrome.
  16. History of meningitis or meningoencephalitis.
  17. Current disease treated with therapy.
  18. Patients with history of severe thrombophilia or under anticoagulant pharmacological therapy which long elimination half-live prevents a rapid transition to heparin (like dabigatran and rivaroxaban).
  19. Presence of any psychiatric illness, as defined by the , or medically unstable illness that means a hindrance to the adherence to rehabilitation and/or to the signature.
  20. Pregnant women or women of childbearing age who are not using an appropriate method of and, moreover, are not willing to continue to use it for the duration of the trial. If the patient is menopausal or sterile, it must be documented in the medical record.
  21. Women who are breastfeeding if unwilling to stop at the time of recruitment.
  22. History of allergy with anaphylactic shock.
  23. Patients with known to any of the of FAB117-HC.
  24. Patients with known hypersensitivity to penicillin, streptomycin, enzymes (trypsin or collagenase), bovine serum or DMSO.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    FAB117-HC (Ph 1)

    Patients with acute traumatic spinal cord injury grading AIS A (8 patients)

    Drug: FAB117-HC

  • Other
    Control group (Ph 2)

    Patients with acute traumatic spinal cord injury grading AIS A or B (up to 20 patients)

    Other: Control group

  • Experimental
    FAB117-HC (Ph 2)

    Patients with acute traumatic spinal cord injury grading AIS A or B (up to 20 patients)

    Drug: FAB117-HC

Interventions

  • DrugFAB117-HC

    (Ph 1) Intramedullary administration. Open label dose escalation, 3 patients in cohort 1 (20 million cells) and 5 patients in cohort 2 (40 million cells)

  • OtherControl group

    (Ph 2) No treatment will be administered

  • DrugFAB117-HC

    (Ph 2) Intramedullary administration of the maximum tolerated dose (20 or 40 million cells)

06

What researchers measure

Primary outcomes

  1. Number of adverse events as a measure of safety and tolerability of a single dose of FAB117-HC when administered by intramedullary injection into the injured spinal cord

    Time frame: One year

Secondary outcomes

  1. Changes in neurological function using the International Standards for Neurological Classification of SCI (ISNCSCI) scale, examinations at 24h, 72h, 7d, 14d, 28d, 90d and 360 days after injection of FAB117-HC

    Time frame: One year

  2. Changes in the functional assessment of Spinal Cord Independence Measure (SCIM III)

    Time frame: Day 28 and Day 90

  3. Changes in Somatosensory-Evoked Potentials (SSEP) electrophysiological assessment test.

    Time frame: Day 28 and Day 90

  4. Changes in Motor-Evoked Potentials (MEP) electrophysiological assessment test

    Time frame: Day 28 and Day 90

07

Study locations

9 of 9 sites recruiting
  • Complexo Hospitalario Universitario A Coruña
    A Coruña, 15006, Spain
    Recruiting
    • Antonio Rodríguez Sotillo, MD, PhD · Principal investigator
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
    Recruiting
    • Miguel Ángel González Viejo, MD, PhD · Principal investigator
  • Hospital Universitario Virgen de las Nieves
    Granada, 18014, Spain
    Recruiting
    • Inmaculada García Montes, MD PhD · Principal investigator
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
    Recruiting
    • Igor Paredes Sansinenea, MD, PhD · Principal investigator
  • Hospital Universitario Virgen del Rocío
    Sevilla, 41013, Spain
    Recruiting
    • Juana María Barrera Chacón, MD, PhD · Principal investigator
  • Complejo Hospitalario de Toledo (HNP y VS)
    Toledo, 45071, Spain
    Recruiting
    • Ángel Gil Agudo, MD, PhD · Principal investigator
  • Hospital Universitari La Fe
    Valencia, 46009, Spain
    Recruiting
    • Teresa Bas, MD, PhD · Principal investigator
  • Hospital Clínico Universitario Lozano Blesa
    Zaragoza, 50009, Spain
    Recruiting
    • Isabel Villarreal, MD PhD · Principal investigator
  • Hospital Universitario Miguel Servet
    Zaragoza, 50009, Spain
    Recruiting
    • Begoña Hidalgo, MD PhD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2016, a primary completion of Jul 2022 and a completion of Jul 2023. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2016
First posted
Sep 28, 2016
Start
Dec 2016
Primary completionEst.
Jul 2022
CompletionEst.
Jul 2023
Last update
Sep 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02917291
Collaborators
Histocell, S.L.
Responsible party
Sponsor
First posted
Sep 28, 2016
Start date
Dec 2016
Primary completion
Jul 2022 (estimated)
Completion
Jul 2023 (estimated)
Last update
Sep 16, 2021

Study contacts

Andrés G Fernández, PhD
Contact
ferreradvancedbiotherapeutics@ferrer.com

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion